01

Two-Dose Neoadjuvant Pembrolizumab Yields 55.6% pCR in Resectable cSCC

A UPMC Hillman phase 2 trial reports 55.6% pathologic complete response with two neoadjuvant pembrolizumab doses in stage II–III cSCC, with RT de-escalated in 93% of responders.